

CERTIFICATE OF ANALYSIS No.: 2025-17287

CLIENT

Nordic Med Can AB, Eriksgatan 4
52135 Falköping, Sweden

SAMPLE *

Kompolti F-GR-12M25



Sample condition: SUITABLE
Sample ID: 2543011
Sample type: Plant material
Batch No.: *

Work order: 2025-113025
Analysis ID: 2025_324
Method ID: PHL_RPC_16C
Method SOP: MET-LAB-001-08

Sample received: 21/10/2025
Start of analysis: 22/10/2025
End of analysis: 23/10/2025
Analyst: Valentina Malin

* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	< LOQ	n/a	
CBDA - Cannabidiolic acid	12.91	0.65	
CBGA - Cannabigerolic acid	0.686	0.089	
CBG - Cannabigerol	0.057	0.017	
CBD - Cannabidiol	0.763	0.076	
THCV - Tetrahydrocannabivarin	< LOQ	n/a	
CBN - Cannabinol	< LOQ	n/a	
Δ⁹-THC - Δ-9-Tetrahydrocannabinol	0.093	0.020	
Δ⁸-THC - Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL - Cannabicyclol	< LOQ	n/a	
CBC - Cannabichromene	0.062	0.014	
Δ⁹-THCA - Δ-9-Tetrahydrocannabinolic acid	0.484	0.082	
CBV - Cannabivarin	< LOQ	n/a	
CBCA - Cannabichromenic acid	0.609	0.061	
CBT - Cannabicitran	< LOQ	n/a	
CBE - Cannabielsoin	< LOQ	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor $k = 2$, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

23/10/2025

Approved by:

mag. Valentina Malin
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate

CERTIFICATE OF ANALYSIS No.: 2023-11101

CLIENT

Nordic Med Can AB, Eriksgatan 4
52135 Falköping, Sweden

SAMPLE *

Santhica hackade buds



Sample condition: SUITABLE
Sample ID: 2304096
Sample type: Plant material
Batch No.: *

Work order: 2023-107263
Analysis ID: 2023_021
Method ID: PHL_RPC_16C
Method SOP: MET-LAB-003-02

Sample received: 27/01/2023
Start of analysis: 27/01/2023
End of analysis: 30/01/2023
Analyst: Blaž Janežič

* Information provided by the client.

CANNABINOID PROFILE	Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV - Cannabidivarin	< LOQ	n/a	_____
CBDA - Cannabidiolic acid	0.263	0.045	█_____
CBGA - Cannabigerolic acid	3.80	0.27	████████████████████
CBG - Cannabigerol	0.169	0.042	█_____
CBD - Cannabidiol	0.166	0.025	█_____
THCV - Tetrahydrocannabivarin	< LOQ	n/a	_____
CBN - Cannabinol	< LOQ	n/a	_____
Δ⁹-THC - Δ-9-Tetrahydrocannabinol	< LOQ	n/a	_____
Δ⁸-THC - Δ-8-Tetrahydrocannabinol	< LOQ	n/a	_____
CBL - Cannabicyclol	< LOQ	n/a	_____
CBC - Cannabichromene	0.0419	0.0092	█_____
Δ⁹-THCA - Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	_____
CBE - Cannabielsoin	< LOQ #	n/a	_____
CBV - Cannabivarin	< LOQ #	n/a	_____
CBCA - Cannabichromenic acid	0.0386 #	0.0089	█_____
CBT - Cannabicitran	< LOQ #	n/a	_____

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor $k = 2$, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

30/01/2023

Approved by:

mag. Janja Ahej
Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar
Chief Technology Officer

End of Certificate